News & Updates

Show Multimedia Only

Ingestible vital sign monitor to aid in diagnosis of sleep-related respiratory disorders

02 Dec 2023 by

A wireless, capsule-like ingestible device can measure multiple vital signs from within the gastrointestinal tract, having the potential to diagnose sleep-related respiratory disorders and capture life-threatening events such as apnoea or opioid overdose, according to a study.

02 Dec 2023

Prior ICI therapy potentially improves COVID-19 outcomes in cancer patients

01 Dec 2023

Previous exposure to immune checkpoint inhibitors (ICIs) does not appear to worsen COVID-19 outcomes but may even improve them in patients with cancer, according to a study.

01 Dec 2023

Dupilumab reduces SCS use in type 2 asthma regardless of prior exacerbations

30 Nov 2023 by

Treatment with dupilumab reduces the use of systemic corticosteroids (SCS) in children with moderate-to-severe asthma, regardless of exacerbation history, according to a post hoc analysis of the VOYAGE and EXCURSION trials presented at APSR 2023.

30 Nov 2023

Simplified, tailored treatment for asthma improves patient outcomes

29 Nov 2023 by

Asthma is a highly prevalent disease that can affect anybody regardless of age, race, and location. The overall burden of asthma remains severe. Despite the range of available therapies and well-established guidelines, there remains a significant unmet need in the management of asthma. [BMC Public Health 2012;12:860; Respir Res 2023;24:169; Eur Respir J 2014;43:343-373]

29 Nov 2023

Pre-eclampsia ups venous thromboembolism risk during pregnancy

29 Nov 2023

Women with a history of pre-eclampsia are at increased risk of venous thromboembolism during pregnancy, according to a study.

29 Nov 2023

COVID-19 infection ups CV risk in people living with HIV

29 Nov 2023 by

People living with HIV (PLWH) who were diagnosed with COVID-19 had a 35-percent higher risk of a major cardiovascular (CV) event in the following year than PLWH without COVID in a Spanish study.

29 Nov 2023

PIBIK: Switching to B/F/TAF maintains HIV suppression through 48 weeks

28 Nov 2023 by

Viral suppression is maintained through 48 weeks in adults with HIV-1 harbouring drug resistance mutations, who switched to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) fixed-dose combination pill from a boosted protease inhibitor (bPI) therapy, according to recent data from the phase IV open-label PIBIK trial.

28 Nov 2023

Convalescent plasma cuts death in mechanically ventilated patients with COVID-19-induced ARDS

28 Nov 2023 by

In the CONFIDENT trial, convalescent plasma (CCP) conferred a mortality benefit for patients with COVID-19-induced acute respiratory distress syndrome (ARDS) who were on invasive mechanical ventilation (IMV).

28 Nov 2023

BOREAS highlights dupilumab potential in COPD

27 Nov 2023 by

In the phase III BOREAS trial, the monoclonal antibody dupilumab conferred multiple benefits for individuals with chronic obstructive pulmonary disease (COPD) and type 2 (T2) inflammation.

27 Nov 2023

Which factors predict pulmonary hypertension in ILD?

26 Nov 2023 by

Multiple risk factors for pulmonary hypertension such as age, sex, and weight, among others, do not appear to influence the severity of interstitial lung disease (ILD), according to a recent study presented at APSR 2023.

26 Nov 2023

News & Updates

Showing Respirology articles

Showing

Specialty:

Ingestible vital sign monitor to aid in diagnosis of sleep-related respiratory disorders

Prior ICI therapy potentially improves COVID-19 outcomes in cancer patients

Dupilumab reduces SCS use in type 2 asthma regardless of prior exacerbations

Simplified, tailored treatment for asthma improves patient outcomes

Pre-eclampsia ups venous thromboembolism risk during pregnancy

COVID-19 infection ups CV risk in people living with HIV

PIBIK: Switching to B/F/TAF maintains HIV suppression through 48 weeks

Convalescent plasma cuts death in mechanically ventilated patients with COVID-19-induced ARDS

BOREAS highlights dupilumab potential in COPD

Which factors predict pulmonary hypertension in ILD?